Uorane_tuga@Uorane_tuga

1Settimana

What made you buy this specific one tho?🧐

Mi piace••Risposta

Jonas Hoffmann@JonathanFrank

1Settimana

@Uorane_tuga

- Reasonable P/E ~19
- EPS rising + buybacks = negative dilution
- Revenue climbing, with upside from oncology pipeline (colorectal, kidney, solid tumors)
- US-based → less regulation hassle
Others may fit, but this one ticks all my boxes.

Mi piace•

👍

11

•Risposta